OncoMatch/Clinical Trials/NCT06730750
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Is NCT06730750 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including BMS-986490 and Bevacizumab for advanced solid tumors.
Treatment: BMS-986490 · Bevacizumab — This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Tumor Agnostic
Disease stage
Required: Stage IIIB, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic cancer therapy (5-FU, irinotecan, oxaliplatin) — metastatic or adjuvant
disease has progressed after systemic cancer therapy in the metastatic or adjuvant setting including 5-FU, irinotecan, and/or oxaliplatin (if available and not contraindicated)
Must have received: anti-PD-1/PD-L1 therapy
must have received and progressed on or after anti-PD-(L)1 therapy, if available
Must have received: standard treatment regimen — advanced or metastatic
must have received and then progressed or been intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting (or have progressed within 6 months of adjuvant therapy)
Cannot have received: therapy targeting CEACAM5
Previously received therapy targeting CEACAM5
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- USC/Norris Comprehensive Cancer Center · Los Angeles, California
- START Midwest · Grand Rapids, Michigan
- John Theurer Cancer Center at Hackensack University Medical Center · Hackensack, New Jersey
- UPMC Hillman Cancer Center · Pittsburgh, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06730750 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior therapy targeting CEACAM5 disqualifies patients from enrollment.
What disease stage is eligible?
Stage IIIB or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify